| Date Checked | 2026-04-21 04:58:41 |
|---|---|
| Graham Number | (PB)nan vs (PE)13.52 |
| Over / Under Value Percentage | 0.00% vs nan% |
| Dividend Yield | 0.00% |
| Dividend Date | 2019-05-10 |
| Symbol | NVAX |
| AssetType | Common Stock |
| Name | Novavax Inc |
| Description | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland. |
| CIK | 1000694 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, UNITED STATES, 20878 |
| OfficialSite | https://www.novavax.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-12-31 |
| MarketCapitalization | 1323040000 |
| EBITDA | 590853000 |
| PERatio | 3.147 |
| PEGRatio | 1.322 |
| BookValue | -0.786 |
| DividendPerShare | None |
| EPS | 2.58 |
| RevenuePerShareTTM | 6.93 |
| ProfitMargin | 0.392 |
| OperatingMarginTTM | 0.142 |
| ReturnOnAssetsTTM | 0.257 |
| ReturnOnEquityTTM | -8.98 |
| RevenueTTM | 1123479000 |
| GrossProfitTTM | 713619000 |
| DilutedEPSTTM | 2.58 |
| QuarterlyEarningsGrowthYOY | -0.381 |
| QuarterlyRevenueGrowthYOY | 0.666 |
| AnalystTargetPrice | 14 |
| AnalystRatingStrongBuy | 0 |
| AnalystRatingBuy | 5 |
| AnalystRatingHold | 1 |
| AnalystRatingSell | 1 |
| AnalystRatingStrongSell | 2 |
| TrailingPE | 3.147 |
| ForwardPE | 2.585 |
| PriceToSalesRatioTTM | 1.178 |
| PriceToBookRatio | 33.2 |
| EVToRevenue | 0.806 |
| EVToEBITDA | 1.839 |
| Beta | 2.648 |
| 52WeekHigh | 11.97 |
| 52WeekLow | 5.8 |
| 50DayMovingAverage | 9.19 |
| 200DayMovingAverage | 8.08 |
| SharesOutstanding | 162936000 |
| SharesFloat | 140469000 |
| PercentInsiders | 4.987 |
| PercentInstitutions | 70.157 |
| ExDividendDate | None |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2026-04-21 04:58:41 |
| fresh | 1 |